| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2010 , Vol 52 , Num 3
ITRACONAZOLE NANOSUSPENSION FOR ORAL DELIVERY: FORMULATION, CHARACTERIZATION AND IN VITRO COMPARISON WITH MARKETED FORMULATION
Unison pharmaceuticals. Ahmedabad, Gujarat, India
Viewed :
17671
-
Downloaded :
5901
Itraconazole was formulated in a nanosuspension to increase the aqueous solubility and to improve its formulation related parameters, dissolution and hence oral bioavailability. Itraconazole nanosuspension was prepared by pearl milling technique using zirconium oxide beads as a milling media, poloxamer 407 as a stabilizer and gycerol as a wetting agent. Effect of various process parameters like, stirring time and ratio of the beads were optimized by keeping Drug:surfactant:milling media (1:3:50) as a constant initially then optimized process parameters were used to optimize formulation parameters by 32 factorial designs. The optimized nanosuspension was lyophilized using mannitol (1:1 ratio) as a cryoprotectant. Characterization of nanosuspension was performed by particle size and size distribution, drug content, scanning electron microscopy, differential scanning calorimetry and X-ray diffraction technique. Optimized nanosuspension showed a mean particle diameter of 294 nm, spherical shape with surface oriented surfactant molecules, which were stabilized formulation, high drug content, no chemical instability and no significant change in crystalline nature after formulation also. The in vitro dissolution profile of optimized formulation compared to pure drug and marketed formulation (Canditral Capsule) using 0.1N hydrochloric acid as dissolution medium showed higher drug release compared to the pure drug and marketed formulation.
Keywords :
NANOSUSPENSION, ITRACONAZOLE, PEARL MILLING TECHNIQUE